Compare Abeona Therapeutics Inc (ABEO) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while iShares Broad USD Investment Grade Corporate Bond trades at $50.74. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| ABEO | USIG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Fixed Income |
52-Week High | $7.23 | $52.69 |
52-Week Low | $4.17 | $50.56 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
USIG trades at $51.09 with no change in the last session. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent news highlights a significant 63.4% increase in short interest as of April 15, 2026 (Defense World), and Fifth Third Securities reduced its stake by 54.7% in the latest quarter (Defense World, 2026-04-13). The ETF maintains regular dividend distributions, with the most recent being $0.20 paid on July 7, 2026.
The outlook for USIG is cautious due to bearish technical signals and rising short interest. Investment opportunities include steady dividend income, but risks involve potential price pressure from increased short selling and institutional selling. Investors should weigh the ETF's fixed-income characteristics against current market sentiment and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
